Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
17 hedge funds and large institutions have $6.27M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.
83% more capital invested
Capital invested by funds: $3.43M → $6.27M (+$2.84M)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GBWM
Granite Bay Wealth Management
Portsmouth,
New Hampshire
|
+$4.53M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$180K |
| 3 |
Morgan Stanley
New York
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$798K |
| 2 |
Goldman Sachs
New York
|
-$496K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$189K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$67.2K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$25.9K |
GERM Hedge Fund Activity: Q3 2023 in Review
17 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q3 2023, worth a combined $6.27M — up 83% from $3.43M a quarter earlier.
Fund positioning in GERM was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 6 trimmed.
The largest buyer was Granite Bay Wealth Management, opening a new position worth an estimated $4.53M. The largest seller was LPL Financial, exiting entirely with an estimated $798K sold.
- 17 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $6.27M of Amplify Treatments, Testing and Advancements ETF stock for Q3 2023, up 83% quarter-over-quarter.
- 2 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q3 2023 and 2 closed out, a net change of 0 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q3 2023 was Granite Bay Wealth Management, an estimated $4.53M added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q3 2023 was LPL Financial, an estimated $798K sold.
Based on aggregated 13F filings for Q3 2023.